Concepts (178)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystitis, Interstitial | 16 | 2024 | 58 | 10.080 |
Why?
|
| Urinary Bladder | 7 | 2023 | 320 | 2.940 |
Why?
|
| Endometriosis | 4 | 2024 | 103 | 2.810 |
Why?
|
| RNA | 7 | 2020 | 99 | 1.400 |
Why?
|
| Polyneuropathies | 2 | 2022 | 11 | 1.350 |
Why?
|
| Fibromyalgia | 2 | 2022 | 26 | 1.320 |
Why?
|
| Pelvic Pain | 4 | 2022 | 23 | 1.280 |
Why?
|
| Gene Expression Profiling | 7 | 2020 | 341 | 1.130 |
Why?
|
| Colitis, Ulcerative | 2 | 2016 | 24 | 0.880 |
Why?
|
| Humans | 30 | 2024 | 34474 | 0.880 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2024 | 13 | 0.860 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2024 | 12 | 0.850 |
Why?
|
| Embryo Transfer | 1 | 2024 | 11 | 0.850 |
Why?
|
| Female | 19 | 2024 | 21490 | 0.840 |
Why?
|
| Anesthetics | 2 | 2021 | 21 | 0.830 |
Why?
|
| Adult | 12 | 2024 | 10015 | 0.830 |
Why?
|
| Embryo Implantation | 1 | 2024 | 59 | 0.820 |
Why?
|
| Opiate Alkaloids | 1 | 2023 | 2 | 0.810 |
Why?
|
| Urinary Diversion | 1 | 2023 | 27 | 0.790 |
Why?
|
| MicroRNAs | 2 | 2024 | 194 | 0.790 |
Why?
|
| Retrospective Studies | 8 | 2024 | 3812 | 0.770 |
Why?
|
| Fatigue Syndrome, Chronic | 1 | 2022 | 7 | 0.760 |
Why?
|
| Hypersensitivity | 1 | 2022 | 26 | 0.750 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 6 | 2016 | 175 | 0.730 |
Why?
|
| Colon | 2 | 2019 | 71 | 0.690 |
Why?
|
| Gene Expression Regulation | 2 | 2014 | 526 | 0.670 |
Why?
|
| Gene Expression | 3 | 2016 | 362 | 0.670 |
Why?
|
| Middle Aged | 11 | 2024 | 12703 | 0.660 |
Why?
|
| Constipation | 1 | 2019 | 12 | 0.590 |
Why?
|
| Physical Therapy Modalities | 1 | 2019 | 84 | 0.580 |
Why?
|
| Anesthesia | 1 | 2019 | 72 | 0.580 |
Why?
|
| Graft Survival | 1 | 2020 | 315 | 0.560 |
Why?
|
| RNA, Messenger | 5 | 2022 | 545 | 0.560 |
Why?
|
| Pilot Projects | 4 | 2024 | 583 | 0.540 |
Why?
|
| Ileum | 1 | 2016 | 16 | 0.500 |
Why?
|
| Control Groups | 1 | 2016 | 5 | 0.500 |
Why?
|
| Pain | 3 | 2023 | 330 | 0.480 |
Why?
|
| Kidney | 1 | 2020 | 528 | 0.480 |
Why?
|
| Intestinal Mucosa | 3 | 2024 | 75 | 0.470 |
Why?
|
| Kidney Transplantation | 1 | 2020 | 515 | 0.460 |
Why?
|
| Young Adult | 5 | 2023 | 2825 | 0.450 |
Why?
|
| Child, Preschool | 4 | 2024 | 1354 | 0.440 |
Why?
|
| Adolescent | 5 | 2023 | 3799 | 0.410 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2024 | 20 | 0.410 |
Why?
|
| Child Development Disorders, Pervasive | 1 | 2013 | 2 | 0.390 |
Why?
|
| Aged | 6 | 2024 | 10998 | 0.390 |
Why?
|
| Crohn Disease | 1 | 2013 | 31 | 0.380 |
Why?
|
| Genomics | 2 | 2022 | 94 | 0.370 |
Why?
|
| Child | 4 | 2024 | 2613 | 0.370 |
Why?
|
| Aged, 80 and over | 4 | 2023 | 4150 | 0.360 |
Why?
|
| Electromagnetic Fields | 2 | 2022 | 30 | 0.360 |
Why?
|
| Male | 10 | 2024 | 20697 | 0.340 |
Why?
|
| Severity of Illness Index | 2 | 2024 | 922 | 0.310 |
Why?
|
| Organ Size | 2 | 2021 | 236 | 0.290 |
Why?
|
| Case-Control Studies | 2 | 2024 | 924 | 0.280 |
Why?
|
| Inflammation | 2 | 2024 | 557 | 0.280 |
Why?
|
| Syndrome | 2 | 2021 | 76 | 0.280 |
Why?
|
| Chronic Disease | 2 | 2023 | 438 | 0.260 |
Why?
|
| Prevalence | 2 | 2024 | 1034 | 0.260 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2005 | 281 | 0.250 |
Why?
|
| Thimerosal | 1 | 2006 | 1 | 0.250 |
Why?
|
| Autistic Disorder | 1 | 2006 | 8 | 0.250 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2006 | 19 | 0.240 |
Why?
|
| Lymphocytes | 1 | 2006 | 59 | 0.240 |
Why?
|
| Heat-Shock Proteins | 1 | 2006 | 44 | 0.240 |
Why?
|
| alpha-Synuclein | 1 | 2006 | 10 | 0.240 |
Why?
|
| Phenotype | 2 | 2020 | 656 | 0.230 |
Why?
|
| Oligonucleotides | 1 | 2005 | 31 | 0.230 |
Why?
|
| Primates | 1 | 2005 | 130 | 0.220 |
Why?
|
| Alcoholism | 1 | 2006 | 103 | 0.220 |
Why?
|
| Fertilization in Vitro | 1 | 2024 | 23 | 0.210 |
Why?
|
| Feces | 1 | 2024 | 43 | 0.210 |
Why?
|
| Sirtuin 1 | 1 | 2024 | 40 | 0.210 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2023 | 44 | 0.190 |
Why?
|
| Proteomics | 1 | 2004 | 106 | 0.190 |
Why?
|
| Mucous Membrane | 1 | 2023 | 28 | 0.190 |
Why?
|
| Endometrium | 1 | 2024 | 183 | 0.190 |
Why?
|
| Cystectomy | 1 | 2023 | 110 | 0.190 |
Why?
|
| Bacteria | 1 | 2023 | 56 | 0.190 |
Why?
|
| Prospective Studies | 2 | 2020 | 2461 | 0.180 |
Why?
|
| Autoimmune Diseases | 1 | 2021 | 49 | 0.170 |
Why?
|
| Nervous System Diseases | 1 | 2021 | 47 | 0.170 |
Why?
|
| Time Factors | 3 | 2021 | 2352 | 0.170 |
Why?
|
| Pregnancy | 1 | 2024 | 1069 | 0.170 |
Why?
|
| Proteome | 1 | 2020 | 41 | 0.160 |
Why?
|
| Risk Factors | 2 | 2020 | 4136 | 0.160 |
Why?
|
| Administration, Intravesical | 1 | 2020 | 28 | 0.160 |
Why?
|
| Urinary Bladder Diseases | 1 | 2020 | 45 | 0.160 |
Why?
|
| Delayed Graft Function | 1 | 2020 | 33 | 0.160 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 589 | 0.150 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2020 | 73 | 0.150 |
Why?
|
| Water | 1 | 2019 | 70 | 0.150 |
Why?
|
| Extracellular Matrix | 1 | 2020 | 260 | 0.140 |
Why?
|
| Animals | 9 | 2014 | 8544 | 0.140 |
Why?
|
| Cosmic Radiation | 1 | 2018 | 13 | 0.140 |
Why?
|
| Hematopoiesis | 1 | 2018 | 33 | 0.140 |
Why?
|
| Age Factors | 1 | 2021 | 1261 | 0.140 |
Why?
|
| Bone Marrow Cells | 1 | 2018 | 125 | 0.130 |
Why?
|
| Compliance | 1 | 2017 | 14 | 0.130 |
Why?
|
| Principal Component Analysis | 1 | 2016 | 73 | 0.120 |
Why?
|
| Area Under Curve | 1 | 2016 | 98 | 0.120 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2016 | 30 | 0.120 |
Why?
|
| Urine | 1 | 2017 | 70 | 0.120 |
Why?
|
| ROC Curve | 1 | 2016 | 176 | 0.120 |
Why?
|
| Quality of Life | 1 | 2022 | 1032 | 0.120 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2018 | 183 | 0.120 |
Why?
|
| Cadaver | 1 | 2016 | 169 | 0.120 |
Why?
|
| Feasibility Studies | 1 | 2016 | 323 | 0.110 |
Why?
|
| Macaca fascicularis | 3 | 2006 | 548 | 0.110 |
Why?
|
| Prognosis | 1 | 2019 | 1603 | 0.110 |
Why?
|
| Neuromuscular Diseases | 1 | 2014 | 17 | 0.110 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2014 | 18 | 0.110 |
Why?
|
| Sweden | 1 | 2014 | 17 | 0.110 |
Why?
|
| Microarray Analysis | 1 | 2014 | 21 | 0.110 |
Why?
|
| Cystoscopy | 1 | 2014 | 28 | 0.110 |
Why?
|
| Treatment Outcome | 2 | 2020 | 3618 | 0.110 |
Why?
|
| Biopsy | 1 | 2014 | 268 | 0.100 |
Why?
|
| Regenerative Medicine | 1 | 2014 | 219 | 0.090 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 2366 | 0.070 |
Why?
|
| Cohort Studies | 1 | 2013 | 1910 | 0.070 |
Why?
|
| Cells, Cultured | 2 | 2006 | 887 | 0.060 |
Why?
|
| Databases, Genetic | 1 | 2006 | 40 | 0.060 |
Why?
|
| Zinc | 1 | 2006 | 33 | 0.060 |
Why?
|
| DNA Primers | 2 | 2003 | 92 | 0.060 |
Why?
|
| Transcription, Genetic | 2 | 2004 | 152 | 0.060 |
Why?
|
| Cerebellum | 1 | 2005 | 27 | 0.060 |
Why?
|
| Up-Regulation | 1 | 2006 | 202 | 0.060 |
Why?
|
| Chromosome Mapping | 1 | 2005 | 193 | 0.060 |
Why?
|
| Self Administration | 1 | 2006 | 385 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 755 | 0.050 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2004 | 11 | 0.050 |
Why?
|
| Protein Array Analysis | 1 | 2004 | 14 | 0.050 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2004 | 28 | 0.050 |
Why?
|
| Parthenogenesis | 1 | 2003 | 7 | 0.050 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2004 | 97 | 0.050 |
Why?
|
| Genetic Markers | 1 | 2004 | 131 | 0.050 |
Why?
|
| Pluripotent Stem Cells | 1 | 2003 | 18 | 0.050 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 2003 | 14 | 0.050 |
Why?
|
| Alcohol Drinking | 1 | 2005 | 260 | 0.050 |
Why?
|
| Neuropeptides | 1 | 2003 | 23 | 0.050 |
Why?
|
| Methylmercury Compounds | 1 | 2002 | 4 | 0.050 |
Why?
|
| Nerve Tissue Proteins | 1 | 2003 | 129 | 0.050 |
Why?
|
| Phospholipases A | 1 | 2002 | 31 | 0.050 |
Why?
|
| Arachidonic Acids | 1 | 2002 | 28 | 0.050 |
Why?
|
| Astrocytes | 1 | 2002 | 64 | 0.050 |
Why?
|
| Rats | 2 | 2003 | 1946 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2003 | 612 | 0.040 |
Why?
|
| Pancreas | 1 | 2020 | 107 | 0.040 |
Why?
|
| Solar Energy | 1 | 2018 | 4 | 0.040 |
Why?
|
| Bystander Effect | 1 | 2018 | 6 | 0.040 |
Why?
|
| Protons | 1 | 2018 | 23 | 0.030 |
Why?
|
| DNA Damage | 1 | 2018 | 96 | 0.030 |
Why?
|
| Tissue Scaffolds | 1 | 2020 | 435 | 0.030 |
Why?
|
| Iron | 1 | 2018 | 121 | 0.030 |
Why?
|
| Tissue Engineering | 1 | 2020 | 700 | 0.030 |
Why?
|
| Drug Discovery | 1 | 2014 | 38 | 0.030 |
Why?
|
| Forecasting | 1 | 2014 | 153 | 0.030 |
Why?
|
| Bioengineering | 1 | 2014 | 77 | 0.030 |
Why?
|
| Stem Cell Transplantation | 1 | 2014 | 228 | 0.020 |
Why?
|
| Genes, MHC Class I | 1 | 2003 | 6 | 0.010 |
Why?
|
| Genes, MHC Class II | 1 | 2003 | 4 | 0.010 |
Why?
|
| Blastocyst | 1 | 2003 | 11 | 0.010 |
Why?
|
| Embryonic and Fetal Development | 1 | 2003 | 12 | 0.010 |
Why?
|
| Intermediate Filament Proteins | 1 | 2003 | 11 | 0.010 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2003 | 73 | 0.010 |
Why?
|
| DNA Probes | 1 | 2003 | 20 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2003 | 20 | 0.010 |
Why?
|
| Stearic Acids | 1 | 2002 | 6 | 0.010 |
Why?
|
| Phospholipases A2 | 1 | 2002 | 25 | 0.010 |
Why?
|
| Phospholipids | 1 | 2002 | 35 | 0.010 |
Why?
|
| Cell Line | 1 | 2003 | 476 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2002 | 148 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2002 | 143 | 0.010 |
Why?
|
| DNA | 1 | 2003 | 235 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2002 | 185 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2003 | 484 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2002 | 923 | 0.010 |
Why?
|
| Neurons | 1 | 2003 | 491 | 0.010 |
Why?
|